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Patients hospitalised for decompensated heart failure 
(DHF) have a high mortality, are at increased risk of 
further cardiovascular events, and experience frequent 
re-admissions to hospital; the accurate identiﬁ  cation of 
high-risk patients before discharge remains a signiﬁ  cant 
clinical challenge. Di Somma and colleagues [1] suggest 
that changes in B-type natriuretic peptide (BNP) concen-
tration measured at admission, after 24 hours and at 
discharge may be useful in identifying patients at risk of 
readmission with a cardiac adverse event after hospitali-
zation for DHF. In their Italian multicentre study, a 
decrease in BNP concentration of >25% 24 hours after 
admission to hospital and a >46% decrease at discharge 
were strong negative prognostic factors for future cardio-
vascular events. An absolute BNP concentration of 
<300 pg/ml at discharge was also negatively predictive. 
Combined, the predictive value was improved with a 
change in BNP concentration of <46% at discharge with 
an absolute BNP concentration of >300 pg/ml giving an 
odds ratio for adverse events of 9.61. Th  e authors 
conclude that high risk patients may beneﬁ  t from further 
treatment in hospital for their DHF but they fall short of 
recommending a treatment regimen and this study does 
not prove that targeting BNP as a treatment aim would 
be beneﬁ  cial.  Th  ese ﬁ   ndings are not unique, but add 
evidential weight to previous preliminary studies showing 
poor outcome amongst patients with DHF who fail to 
decrease their BNP concentrations during their hospital 
admission [2]
Increased plasma BNP concentration is an independent 
predictor of cardiovascular events after a diagnosis of 
heart failure, even after adjusting for traditional risk 
factors [3]. In the Valsartan Heart Failure Trial (Val-
HeFT) [4] a higher mortality was observed in stable 
subjects with chronic heart failure if their BNP concen-
tration measured at the start of the study was >238 pg/ml, 
compared with those with a concentration <41  pg/ml, 
irrespective of the treatment modality, and in a 
systematic review [5] of BNP measurements in patients 
with known heart failure, the relative risk of death was 
calculated to increase 35% for every 100 pg/ml increase 
in BNP on admission to hospital. Dhaliwal and colleagues 
[6] studied patients at follow-up clinic after admission for 
heart failure and patients with either a BNP concentration 
<350 pg/ml or a large percentage decrease of BNP concen-
tration at follow-up had a longer event-free survival.
BNP has a short life and has been shown to decrease in 
patients with heart failure in response to therapy, thus 
making it a potential biomarker of treatment [7]. What is 
less clear is if it is useful as a target for treatment. Th  e 
Systolic Heart Failure Treatment Supported by BNP 
(STARS-BNP) trial [8] evaluated BNP-guided care versus 
standard care in 220 patients admitted with chronic heart 
failure; no overall diﬀ  erence in mortality was observed, 
but patients in the BNP-guided group were more likely to 
have adjustments made to their medications and were 
less likely to suﬀ  er cardiovascular events in the follow-up 
period (median 15 months).
BNP is a 32 amino acid peptide released by the 
ventricles, secondary to stretch of the cardiac myocytes. 
Concentrations of it can change very rapidly and it can 
Abstract
The measurement of B-type natriuretic peptide (BNP) 
is recommended for the diagnosis of decompensated 
heart failure, the prognosis of chronic heart failure is 
worse if BNP is increased and studies suggest that BNP 
is useful to guide therapy. A study by Di Somma and 
colleagues adds to the body of evidence showing that 
patients with a marked decrease in BNP concentrations 
during their hospital admission are less likely to be 
readmitted with a further adverse cardiac event than 
patients in whom BNP fails to decrease. However, the 
wider interpretation of BNP concentrations in critically 
ill patients with other conditions remains uncertain.
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© 2010 BioMed Central Ltdcause both natriuretic and vasodilatory eﬀ  ects, counter-
ing the renin-angiotensin system. Stretch of myocytes is 
not exclusive to heart failure and, indeed, in critically ill 
patients many conditions have been shown to increase 
BNP; for example, sepsis [9], acute lung injury [10], 
pulmonary embolism [11] and intracerebral haemorrhage 
[12]. Some distinctions can be made in terms of absolute 
BNP concentrations observed in diﬀ  erent conditions, but 
the plethora of potential causes of cardiac dysfunction 
and thus BNP release in patients with complex multi-
organ dysfunction has limited the interpretation of BNP 
concentrations in the critical care setting. Rudiger [9] 
found that BNP levels in patients with sepsis were similar 
to those in patients with DHF and that cardiac index and 
pulmonary artery capillary wedge pressure were more 
useful in diagnosing DHF. Furthermore, all attempts to 
correlate BNP concentrations with cardiovascular 
measure  ments (for example, pulmonary capillary wedge 
pressure, left ventricular stroke work index and cardiac 
index) have shown only weak correlations at best [13].
Forﬁ  a and colleagues [13] investigated the relationship 
between pulmonary capillary wedge pressure and BNP 
and found only a weak correlation. However, they also 
observed a strong association between estimated glome-
ru lar  ﬁ  ltration rate and BNP over and above any evidence 
of raised ﬁ  lling pressures and concluded that complex 
interactions must occur between the kidneys and the 
heart. More recently, Park and colleagues [14] have 
suggested that BNP is valuable in the assessment and 
prediction of outcome in cardio-renal syndrome type 4. It 
is clear that the interpretation of BNP concentrations in 
critical care is fraught with diﬃ     culty, but in selected 
patients there are indications that its use may be of value 
in predicting outcome and perhaps in the future also in 
guiding therapy
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